Abstract 298: Fibrate use in patients with type 2 diabetes [Poster Session III]
In conclusion, the prevalence of atherogenic dyslipidemia among patients with type 2 diabetes has increased significantly over the past decade. However, fibrate use in all patients with type 2 diabetes, including those specifically with atherogenic dyslipidemia, has remained constant throughout the observation period, despite lack of conclusive evidence supporting its use.
Source: Circulation: Cardiovascular Quality and Outcomes - Category: Cardiology Authors: McCoy, R. G., Van Houten, H. K., Shah, N. D. Tags: Poster Session III Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Coronary Heart Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fenofibrate | Gemfibrozil | Heart | Heart Disease | Pancreatitis | Statistics | Stroke | Tricor